Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib Rechallenge in Ovarian Cancer With Oligometastatic Progression
NCT06180356Phase 2Recruiting
- Sponsor
- MEDSIR
- Start
- Dec 2024
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of niraparib in ovarian cancer, sponsored by MEDSIR. Primary endpoint: Progression-Free Survival at 7 months. Started Dec 2024; status: recruiting.
02
Drugs
niraparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06180356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06180356.